Royalty Pharma (RPRX) Total Non-Current Liabilities (2019 - 2026)
Royalty Pharma (RPRX) posted Total Non-Current Liabilities of $9.2 billion for Q1 2026, down 5.67% sequentially from $9.8 billion in Q4 2025, and up 18.31% YoY from $7.8 billion in Q1 2025.
Royalty Pharma (RPRX) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Total Non-Current Liabilities for 8 years, with the latest figure at $9.2 billion in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 18.31% year-over-year to $9.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.2 billion (up 18.31% YoY) and the FY2025 annual result came in at $9.8 billion, up 24.17% from the prior year.
- Total Non-Current Liabilities eased to $9.2 billion in Q1 2026 per RPRX's latest filing, from $9.8 billion in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $9.8 billion in Q4 2025 and troughed at $6.3 billion in Q3 2023.
- A 5-year average of $7.7 billion and a median of $7.5 billion in 2023 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities declined 13.62% in 2023, then increased 25.15% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $7.3 billion in 2022, then dropped by 13.57% to $6.3 billion in 2023, then advanced by 25.15% to $7.9 billion in 2024, then grew by 24.17% to $9.8 billion in 2025, then decreased by 5.67% to $9.2 billion in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $9.2 billion, $9.8 billion, and $9.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 378.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.32 Bn |
| Mar 31, 2026 | 9.23 Bn |
| Dec 31, 2025 | 9.78 Bn |
| Sep 30, 2025 | 9.22 Bn |
| Jun 30, 2025 | 8.68 Bn |
| Mar 31, 2025 | 7.80 Bn |
| Dec 31, 2024 | 7.88 Bn |
| Sep 30, 2024 | 7.78 Bn |
| Jun 30, 2024 | 7.88 Bn |
| Mar 31, 2024 | 6.26 Bn |
| Dec 31, 2023 | 6.30 Bn |
| Sep 30, 2023 | 6.26 Bn |
| Jun 30, 2023 | 7.30 Bn |
| Mar 31, 2023 | 7.24 Bn |
| Dec 31, 2022 | 7.29 Bn |
| Sep 30, 2022 | 7.25 Bn |
| Jun 30, 2022 | 7.29 Bn |
| Dec 31, 2021 | 7.27 Bn |
| Dec 31, 2020 | 6.12 Bn |
| Sep 30, 2020 | 6.08 Bn |